Xenon Pharmaceuticals Inc. $XENE Stake Decreased by Nan Fung Trinity HK Ltd.

Nan Fung Trinity HK Ltd. reduced its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 57.0% in the third quarter, HoldingsChannel.com reports. The fund owned 247,765 shares of the biopharmaceutical company’s stock after selling 327,979 shares during the quarter. Nan Fung Trinity HK Ltd.’s holdings in Xenon Pharmaceuticals were worth $9,214,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in XENE. Covestor Ltd grew its position in Xenon Pharmaceuticals by 418.5% in the third quarter. Covestor Ltd now owns 674 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 544 shares in the last quarter. GAMMA Investing LLC increased its stake in Xenon Pharmaceuticals by 60.2% in the third quarter. GAMMA Investing LLC now owns 830 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 312 shares during the last quarter. Global Retirement Partners LLC purchased a new stake in Xenon Pharmaceuticals during the second quarter valued at about $53,000. Quantbot Technologies LP purchased a new stake in Xenon Pharmaceuticals during the second quarter valued at about $57,000. Finally, Axiom Investment Management LLC purchased a new stake in Xenon Pharmaceuticals during the first quarter valued at about $58,000. 95.45% of the stock is owned by institutional investors.

Trending Headlines about Xenon Pharmaceuticals

These are some of the XENE headlines that stood out recently:

• Negative Sentiment: HC Wainwright trimmed its EPS forecasts for 2026–2030, including estimates of losses of $4.53 per share in 2026 and $4.90 in 2027. The changes were generally modest, but weaker projected earnings could weigh on sentiment. Xenon Pharmaceuticals analyst estimates
• Neutral Sentiment: Despite the lower estimates, HC Wainwright reiterated its Buy rating on XENE. The reports provide no new clinical or business developments, so the estimate revisions are the main reported catalyst.

Xenon Pharmaceuticals Stock Down 2.6%

Shares of Xenon Pharmaceuticals stock opened at $40.99 on Friday. Xenon Pharmaceuticals Inc. has a 52-week low of $33.38 and a 52-week high of $72.66. The company has a fifty day moving average of $41.53 and a 200-day moving average of $52.14.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Monday, November 9th. The biopharmaceutical company reported ($1.11) EPS for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.02. Analysts predict that Xenon Pharmaceuticals Inc. will post -4.59 earnings per share for the current fiscal year.

Insider Buying and Selling at Xenon Pharmaceuticals

In related news, CFO Thomas Patrick Kelly acquired 15,000 shares of the firm’s stock in a transaction dated Wednesday, September 30th. The shares were purchased at an average price of $37.32 per share, for a total transaction of $559,800.00. Following the completion of the acquisition, the chief financial officer owned 15,000 shares in the company, valued at approximately $559,800. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, insider Christopher Kenney sold 7,068 shares of Xenon Pharmaceuticals stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $60.25, for a total value of $425,847.00. Following the completion of the transaction, the insider owned 2 shares in the company, valued at approximately $120.50. This represents a 99.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 2.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on XENE shares. HC Wainwright reaffirmed a “buy” rating on shares of Xenon Pharmaceuticals in a research note on Friday, September 18th. Wall Street Zen lowered Xenon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Sunday, October 11th. Robert W. Baird decreased their price objective on Xenon Pharmaceuticals from $97.00 to $90.00 and set an “outperform” rating on the stock in a report on Friday, September 18th. Jefferies Financial Group reissued a “buy” rating and set a $90.00 price objective on shares of Xenon Pharmaceuticals in a report on Monday, September 28th. Finally, Royal Bank Of Canada dropped their target price on Xenon Pharmaceuticals from $81.00 to $70.00 and set an “outperform” rating for the company in a research report on Friday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $71.31.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for neurological disorders. The company’s research emphasizes ion channels, proteins that help regulate the electrical activity of nerve cells. Its lead program is azetukalner, formerly known as XEN1101, an oral Kv7 potassium-channel opener being developed for seizure disorders, including focal epilepsy. Xenon is also advancing other drug candidates aimed at neurological conditions. Founded in 1996, Xenon is headquartered in Burnaby, British Columbia, and conducts drug development activities in North America.